COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortexomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Protocol No
JANSSEN-JNJ-68284528-MMY3002
Principal Investigator
Binod Dhakal
Phase
III
Summary
To compare the effects of JNJ-68284528; the product being studied which is a CAR-T cell therapy, with the effects of pomalidomide, bortezomib and dexamethasone (called “PVd”) or daratumumab, pomalidomide and dexamethasone (called “DPd”).
Description
NJ-68284528 a CAR-T directied against BCMA vs PVd or DPd in pt with rr MM (CARTITUDE-4)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL